Annias Immunotherapeutics, Inc., is a clinical stage company focused on the development of novel immunotherapeutic approaches to treat cancers that contain Cytomegalovirus (CMV). The company’s product candidates are based on a patented and proprietary immunotherapeutic platform, which harnesses the body’s immune system to recognize tumor cells that contain CMV. Examples include Glioblastoma Multiforme (a lethal brain tumor) as well as many breast, prostate and colorectal cancers.

For more information, please contact:

John H. Sampson, MD, PhD, MBA

President and CEO